Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up

Bone Marrow Transplantation volume 58, pages 437–439 (2023)Cite this article

Subjects

Abstract

Patients with high-risk lymphoma have a poor prognosis when treated with standard chemoimmunotherapy. This retrospective study included 23 high-risk lymphoma patients with a median age at diagnosis of 59 (range, 35–68) years. They received 2 cycles of R-COPADM and 2 cycles of CYVE, completed by ASCT for fit patients. With a median follow-up of 46 (range, 3–78) months, three (13%) patients in the cohort died. Nearly half of the patients had an ECOG performance status of 2 or 3. Most patients in the cohort (91%, n = 21) had Ann Arbor stage III-IV disease, and 88% (n = 20) had an IPI of 3 to 5. LDH levels were elevated in 83% (n = 19) of patients. Overall, 30% of patients were identified as having double-expressor lymphoma and 22% as having DHL, while two patients (9%) had THL. The origin of the lymphoma was GC B-cell-like in 15 patients (65%) and ABC-like in 8 patients (35%). Cumulative incidence of relapse at 46 months was 14% (95% CI, 5–37), while overall survival was 87% (95% CI, 64–95) and progression-free survival was 83% (95% CI, 60–93). These results showed the efficacy and an acceptable safety profile of the R-COPADM/CYVE/ASCT regimen in high-risk lymphoma, including patients with DHL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Data availability

The data sets generated and / or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high-risk, mature B-Cell Non-Hodgkin’s Lymphoma in Children. N Engl J Med. 2020;382:2207–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130:867–74.

    Article  CAS  PubMed  Google Scholar 

  3. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. JCO. 2017;35:2260–7.

    Article  CAS  Google Scholar 

  4. Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13:175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Dunleavy K, Gross TG. Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective. Blood 2018;132:369–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shi X, Liu X, Li X, Li Y, Lu D, Sun X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021;11:754964.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, et al. High risk diffuse large B cell lymphoma: a comparison of aggressive subtypes treated with dose adjusted chemotherapy-the university of Texas MD Anderson eExperience. Blood 2016;128:106–106.

    Article  Google Scholar 

  8. Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, et al. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020;4:1906–15.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Blay J, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin’s lymphoma of patients with no known cause of immunosuppression [see comments]. Blood. 1995;86:2922–9.

    Article  CAS  PubMed  Google Scholar 

  10. Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, et al. Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. haematol [Internet]. 2021 Jul 22 [cited 2022 Jul 20]; Available from: https://haematologica.org/article/view/haematol.2021.278638

  11. McMillan AK, Phillips EH, Kirkwood AA, Barrans S, Burton C, Rule S, et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Ann Oncol. 2020;31:1251–9.

    Article  CAS  PubMed  Google Scholar 

  12. Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia. 2021;35:522–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the team of (Laboratoire d’Anatomie Pathologique, Hopital Saint-Antoine) for their dedication and help with the diagnosis of lymphoma patients.

Author information

Author notes

  1. These authors contributed equally: Tamim Alsuliman, Nicolas Stocker

Authors and Affiliations

  1. Sorbonne University, Paris, France

    Tamim Alsuliman, Nicolas Stocker, Elise Corre, Rémy Dulery, Simona Sestili, Laure Ricard, Florent Malard, Mohamad Mohty, Paul Coppo & Zora Marjanovic

  2. Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France

    Tamim Alsuliman, Nicolas Stocker, Elise Corre, Rémy Dulery, Simona Sestili, Laure Ricard, Florent Malard, Mohamad Mohty, Paul Coppo & Zora Marjanovic

  3. INSERM, UMRs 938, Centre de Recherche Saint-Antoine, Paris, France

    Tamim Alsuliman, Nicolas Stocker, Elise Corre, Rémy Dulery, Simona Sestili, Laure Ricard, Florent Malard, Mohamad Mohty & Zora Marjanovic

Authors
  1. Tamim Alsuliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Stocker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elise Corre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rémy Dulery
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simona Sestili
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laure Ricard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Florent Malard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paul Coppo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zora Marjanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TA, NS, and ZM designed the study, TA and NS collected the data, and all authors recruited patients. TA, NS, and ZM prepared the manuscript for publication. All authors analyzed the data, reviewed the manuscript, and agreed to its submission for publication.

Corresponding author

Correspondence to Zora Marjanovic.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alsuliman, T., Stocker, N., Corre, E. et al. Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up. Bone Marrow Transplant 58, 437–439 (2023). https://doi.org/10.1038/s41409-022-01902-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-022-01902-4

This article is cited by

Search

Advanced search

Quick links